Interestingly, we observed a neuropathology-associated inversion of the association between rs679515 major allele dosage and these hematological traits (Supplementary Fig. 2B, Supplementary Dataset 5), whereby major allele dosage was positively associated with hematocrit/RBC/Hb (and inversely associated with the presence of anemia) in subjects with low NFT burden (Braak stage: 0–II), and inversely associated with hematocrit/RBC/Hb (and positively associated with the presence of anemia) in subjects with high NFT burden (Braak stage: V–VI). Here, GSTM1 is linked to anemia (phenotype).